ROLE AND CLINICAL SIGNIFICANCE OF IL-33 IN PATIENTS WITH ASTHMA
Journal
Македонски медицински преглед = Macedonian Medical Review
Date Issued
2017
Author(s)
Gjorchev, Angleko
Kaeva, Biserka
Goseva, Zlatica
Dimitrievska, Deska
Pejkovska, Sava
Minov, Jordan
Abstract
Introduction. Asthma is a chronic inflammatory
disease of the airways in which many cells play a role
with secreting a variety of mediators responsible for
the clinical manifestation of asthma. It is assumed that
IL-33 is one of the earliest-released mediators and can
orchestrate the immune cascade of the disease.
The aimof this study was to examine the role and clinical significance of IL-33 as a new and insufficiently explored mediator of inflammation in patients with
uncontrolled moderate asthma.
Methods. The study included 87 patients with asthma.
Serum IL-33 was measured in all patients by ELISA
method. The obtained data were statistically
analyzedusing the Kolmogorov-Smirnov and ShapiroWilk's test. Qualitative data were presented in absolute
and relative numbers, and quantitative data were
presented with measures of descriptive statistics.
Statistically significant values were considered for p
<0.05.
Results. Majority of included patients were female
(75.86%). The average age of patients was 42.3±15.9
years. The results of IL-33 in all patients were
significantly increased compared to the reference
value of IL-33 which is 0 pg/ml. The average values of
IL-33 ranged from 6.47±29.3 and they were insignificantly higher in the group with female patients compared to males (p=0.27), and insignificantly correlated
with age (p=0.26).
Conclusion. Even though a limited number of studies
have explored the IL-33, results have shown higher serum level of IL-33 in asthma patients compared to
healthy people, emphasizing the fact that IL-33 is an
attractive candidate for targeted therapy and prognosis
in asthma patients.
disease of the airways in which many cells play a role
with secreting a variety of mediators responsible for
the clinical manifestation of asthma. It is assumed that
IL-33 is one of the earliest-released mediators and can
orchestrate the immune cascade of the disease.
The aimof this study was to examine the role and clinical significance of IL-33 as a new and insufficiently explored mediator of inflammation in patients with
uncontrolled moderate asthma.
Methods. The study included 87 patients with asthma.
Serum IL-33 was measured in all patients by ELISA
method. The obtained data were statistically
analyzedusing the Kolmogorov-Smirnov and ShapiroWilk's test. Qualitative data were presented in absolute
and relative numbers, and quantitative data were
presented with measures of descriptive statistics.
Statistically significant values were considered for p
<0.05.
Results. Majority of included patients were female
(75.86%). The average age of patients was 42.3±15.9
years. The results of IL-33 in all patients were
significantly increased compared to the reference
value of IL-33 which is 0 pg/ml. The average values of
IL-33 ranged from 6.47±29.3 and they were insignificantly higher in the group with female patients compared to males (p=0.27), and insignificantly correlated
with age (p=0.26).
Conclusion. Even though a limited number of studies
have explored the IL-33, results have shown higher serum level of IL-33 in asthma patients compared to
healthy people, emphasizing the fact that IL-33 is an
attractive candidate for targeted therapy and prognosis
in asthma patients.
Subjects
File(s)![Thumbnail Image]()
![Thumbnail Image]()
Loading...
Name
MMP 71(1) 2017 (1).pdf
Size
4.76 MB
Format
Unknown
Checksum
(MD5):a408ba99c1d03b3a3f41a7a014649e50
Loading...
Name
Role_and_Clinical_Significance_of_Il-33_in_Patient.pdf
Size
1.1 MB
Format
Adobe PDF
Checksum
(MD5):3e4c025f3d103e637f3cb734b9f4e757